Ir para conteúdo

Beta-Talassémia Intermédia e Minor

Indução Farmacológica da Síntese da Hemoglobina Fetal

Hidroxiureia (Hidroxicarbamida)

Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (abre uma nova janela)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Fonte‎: Hemoglobin 2014;38(1):44-8.

Indexado‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (abre uma nova janela)

Hydroxyurea in thalassemia intermedia--a promising therapy. (abre uma nova janela)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Fonte‎: Ann Hematol 2005;84(7):441-6.

Indexado‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (abre uma nova janela)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (abre uma nova janela)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Fonte‎: J Clin Pathol 2010;63(2):147-50.

Indexado‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (abre uma nova janela)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (abre uma nova janela)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Fonte‎: Eur J Haematol 2010;84(1):52-8.

Indexado‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (abre uma nova janela)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (abre uma nova janela)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Fonte‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indexado‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (abre uma nova janela)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (abre uma nova janela)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Fonte‎: Ann N Y Acad Sci 2005;1054:250-6.

Indexado‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (abre uma nova janela)

Eritropoetina Recombinante (Isolada ou Combinada com Outros Agentes)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (abre uma nova janela)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fonte‎: Acta Haematol 2004;111(4):189-95.

Indexado‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (abre uma nova janela)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (abre uma nova janela)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Fonte‎: Blood Purif 2004;22(5):453-60.

Indexado‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (abre uma nova janela)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (abre uma nova janela)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Fonte‎: Br J Haematol 2011;154(2):281-4.

Indexado‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (abre uma nova janela)